3rd Quarter - Report

FORBES-TATE for AMGEN USA, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to prescription drug pricing; Issues related to H.R. 2693 (116th Congress) - To amend title XVIII of the Social Security Act to improve access to, and utilization of, bone mass measurement benefits under part B of the Medicare program by establishing a minimum payment amount under such part for bone mass measurement.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2693 (117th)

Taxation/Internal Revenue Code TAX

Issues related to the implementation of international tax and tax reform (Public Law No: 115-97); Issues related to Puerto Rico tax.

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260).

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Issues related to Biosimilars.

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.